Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Affinivax
Biotech
GSK axes vaccine from $2.1B deal, switches to preclinical heir
GSK has axed a pneumococcal 24-valent vaccine for adults from its $2.1 billion Affinivax takeover in favor of a preclinical 30-plus valent shot.
Nick Paul Taylor
Oct 30, 2024 7:06am
GSK inks $3.3B Affinivax buyout to challenge Pfizer blockbuster
May 31, 2022 5:19am
Merck's Vaxneuvance lead departs for Affinivax—Chutes & Ladders
Aug 13, 2021 9:30am
Merck's Vaxneuvance lead departs to help develop rival vaccine
Aug 9, 2021 8:20am
Affinivax nabs huge $226M funding round
Jan 8, 2021 8:35am
Affinivax banks $120M for vaccines against hospital superbugs
Apr 23, 2020 7:00am
